ABBV.US AbbVie Inc

Healthcare Biotechnology USA Stocks
294.45 USD
Close of Nov 13, 2026
188.25 302.93
Market cap
USD 520B
P/E
50.6x
P/B
50.46x
ROE
-
Dividend yield
2.24%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is ABBV.US undervalued?

Graham number

The Graham number of AbbVie Inc cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

AbbVie Inc fundamental analysis

No fundamental analysis for AbbVie Inc yet.

AbbVie Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About AbbVie Inc

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung canc…

Full company profile